Predictive Biomarkers in Late Onset Neutropenia Associated with Rituximab
Ali Ogul1, Semra Paydas2, Abdullah Evren Yetisir2, Cem Mirilli3, Mahmut Buyuksimsek11Department of Medical Oncology, Adana City Training and Research Hospital, Adana, Turkey, 2Department of Medical Oncology, Cukurova University Faculty of Medicine, Balcali, Adana, Turkey, 3Department of Medical Oncology, Erzurum Ataturk University Faculty of Medicine, Erzurum, Turkey
Objectives: The aim of this study is to determine the biomarkers in LON (Late Onset Neutropenia) associated with rituximab using in lymphoproliferative diseases (LPDs). Methods: : In this retrospective study 22 cases with LPD treated by rituximab containing regimen and followed at least one year in our center were evaluated for LON. Results: Grade I, II and IV neutropenia were detected in five, five and one cases, respectively. Lowest neutrophil/lymphocyte ratio (NLR) was 1.2 and 1.7 in cases with and without LON, respectively. Neutropenia developed in 8 of 15 cases with Diffuse large B cell lymphoma (DLBCL), 2 of 2 cases with Follicular Lymphoma (FL) and one case of Small lymphocytic lymphoma (SLL). According to prophylactic Granulocyte colony-stimulating factor (G-CSF) using, neutropenia was detected in all cases given prophylaxis while 6 of 17 cases without prophylaxis. Mean rituximab dose was 4870 mg in cases developing neutropenia while it was 4162 mg in cases without neutropenia. Conclusion: Lower NLR at the end of treatment cycle, G-CSF using with prophylaxis aim, extranodal involvement and more than 4 gr rituximab using were found as the predictive factors for LON associated with rituximab. Keywords: Lymphoma, neutropenia, rituximab
Cite This Article
Ogul A, Paydas S, Yetisir A, Mirilli C, Buyuksimsek M. Predictive Biomarkers in Late Onset Neutropenia Associated with Rituximab. EJMI. 2020; 4(4): 428-432
Corresponding Author: Ali Ogul